slides · global inventory
53 Jobs To Be Done
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 1,583
Current window 1,051-1,080
Pages 53
Rows per page 30
Loop
1,051-1,080 of 1,583
27
The charts show the progression of antibody variants over generations, highlighting the improvement in ACE score and naturalness metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The slide uses a process diagram to illustrate the 'in silico' lead optimization workflow.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
The slide uses a process flow diagram to show the integration of AI in drug development.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
21
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number-line to show age of diagnosis, followed by key metrics on complication rates.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
22
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
23
The slide uses a process flow diagram to show the metabolic block (CBS deficiency) and the therapeutic intervention point.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
24
The slide uses a biological process diagram to contrast normal intracellular metabolism with the therapeutic effect of the drug in the plasma.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
04
Includes a faint background image of a vial and syringe.Aldeyra Therapeutics | Results Presentation Deck | 13 slides · Aldeyra Therapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
10
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses chemical structure diagrams to illustrate the relationship between the racemate and its enantiomers.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
Data source: Zanos et al., 2016. The charts show dose-dependent reduction in immobility time.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a third-party study (Yang et al., 2015) to support the claim of a superior therapeutic index for R-ketamine.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide contrasts the therapeutic benefit (MADRS) with the lack of side effects (CADSS) compared to S-Ketamine benchmarks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
CADSS = Clinician administered dissociative states scale. Data points are clustered by time interval.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide uses a standard clinical trial flow diagram (randomization to treatment arms).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The slide uses a comparison structure to contrast safety/tolerability goals against efficacy goals.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The chart compares 25mg, 10mg, and 1mg (comparator) dosages. Statistical significance is marked with asterisks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide outlines the study arms, randomization ratios, and primary endpoint timing for two distinct clinical trials.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a list of three key regulatory takeaways followed by a forward-looking implication for the pipeline.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide introduces the drug candidate VLS-01, providing its chemical identity and current clinical trial status.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The chart displays statistical significance markers (p-values) at Day 1, Day 2, and Day 7.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
26
The slide uses a process flow diagram to represent clinical trial cohorts and SMG (Safety Monitoring Group) review gates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
27
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
Slide 30. Includes statistical significance markers (*, **, ***).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit